Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.
Sarat Chandarlapaty, MD, PhD
Advertisement
Articles by Sarat Chandarlapaty, MD, PhD
Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.
Advertisement
Latest Updated Articles
Dr. Chandarlapaty on Role of the PI3K Pathway in Breast CancerPublished: August 29th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5